Anti-Inflammatory Mechanism
GHK-Cu attenuated CuSO4 or LPS-induced inflammation in zebrafish larvae model via JAK1 pathway downregulation and IL-10 elevation.
[2]A naturally occurring tripeptide-copper complex found in human plasma, urine, and saliva. Plasma levels decline roughly 60 percent by age 60, contributing to age-related decline in tissue repair capacity. GHK-Cu binds copper ions with high affinity and modulates expression of over 4,000 human genes toward regeneration, anti-inflammatory, and antioxidant phenotypes.
At a glance
- Type
- Naturally occurring tripeptide-copper complex
- Found in
- Human plasma, urine, and saliva; plasma levels decline roughly 60 percent by age 60
- Routes
- Topical (strongest evidence), subcutaneous, microneedling adjunct
- Gene modulation
- Over 4,000 human genes toward regeneration, anti-inflammatory, and antioxidant phenotypes
- Regulatory
- Injectable protocols investigational; topical formulations carry decades of cosmetic use history
- Contraindications
- Wilson disease and other copper metabolism disorders
What the research supports
GHK-Cu has one of the deepest and longest-running evidence bases in the regenerative peptide space, with 2025 to 2026 work expanding mechanism and application.
Mitochondrial and Antioxidant Activity
Delays aging in C. elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 antioxidant pathways.
[3]Fascia Regeneration via Copper Delivery
Golgi-targeted copper delivery strategy enhanced copper-dependent protein activity for fascia regeneration applications.
[5]Radiation-Induced Skin Injury
Injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy in radiation-induced skin injury.
Summary of key findings
Over 4,000 Genes Modulated
Modulates the human transcriptome toward a younger expression profile across skin, hair, wound healing, and connective tissue.
Plasma Levels Drop With Age
Roughly 60 percent decline by age 60 mirrors clinical decline in tissue repair capacity.
Topical Safety Unmatched
Decades of cosmetic use history with minimal adverse events; topical formulations are the strongest evidence base.
Stack Foundation
Pairs with TB-500, BPC-157, retinoids, and growth factors in regenerative skincare and tissue protocols.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Topical Application (Strongest Evidence)
- 0.05 to 3 percent formulations applied 1 to 2 times daily.
- Subcutaneous Research and Clinical Use
- Typical 1 to 2 mg daily or 3 to 5 times per week, reconstituted in bacteriostatic water.
- Microneedling Adjunct
- Combined with topical formulation immediately post-procedure.
- Cycling
- Most injectable protocols run 4 to 8 week courses with optional 2 week breaks; topical use can be continuous.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| GHK-Cu 50 mg / 2 mL | 1 to 2 mg | 4 to 8 units | Daily | 0.25 mg per unit. 30 days on / 14 days off. |
| GHK-Cu 75 mg / 2 mL | 1 to 2 mg | about 3 to 5 units | Daily | 0.375 mg per unit. 30 days on / 14 days off. |
| GHK-Cu 100 mg / 3 mL | 1 to 2 mg | 3 to 6 units | Daily | 0.33 mg per unit. 30 days on / 14 days off. |
| GHK-Cu Copper Peptide | 2 mg | Per protocol | Daily | AM or PM empty stomach SC. 4 months. |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
GHK-Cu is one of the most well-characterized regenerative peptides, with foundational research going back to 1973 when Pickart first identified it in human albumin. Plasma levels drop roughly 60 percent by age 60, which mirrors the clinical decline in tissue repair capacity seen in older patients. It is not a single-pathway peptide: it modulates over 4,000 genes toward a younger expression profile, which is why effects appear across skin, hair, wound healing, and connective tissue.
Topical formulations carry the strongest safety record; injectable protocols are still investigational and should be framed that way with patients. 2026 data confirms strong anti-inflammatory and antioxidant action through JAK1 suppression and DAF-16/SKN-1 activation. Stacks well with TB-500 and BPC-157 in tissue repair protocols, and with topical retinoids and growth factors in anti-aging regimens.
Skin and Hair Regeneration
Photodamage repair, wound healing, follicle stimulation, atrophic scarring.
Anti-Inflammatory Antioxidant
JAK1 suppression, ROS reduction, mitochondrial function preservation.
Stack Foundation
Pairs with TB-500, BPC-157, retinoids, and growth factors.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Pickart et al., 2012 GHK-Cu in cognitive health and aging review
- 2Hu et al., 2026 GHK-Cu anti-inflammatory in zebrafish larvae model
- 3Wen et al., 2026 GHK-Cu delays aging in C. elegans via mitochondrial and DAF-16/SKN-1 pathways
- 4Renke and Chinellato, 2026 Therapeutic peptides in aesthetic, metabolic, and endocrine conditions
- 5Wang et al., 2025 Golgi-targeted copper delivery for fascia regeneration
Regulatory status, cautions and contraindications
Contraindications and Cautions
Contraindicated in Wilson disease and other copper metabolism disorders. Active malignancy: caution due to pro-angiogenic activity. Pregnancy and lactation: insufficient safety data; avoid.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.